Skip to search formSkip to main contentSkip to account menu

ABT-348

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase
AbstractRET (rearranged during transfection) tyrosine kinase is a promising target for several human cancers. Abt-348, Birb-796… 
2013
2013
Abstract 3450: ABT-348 in combination with inhibition of CDK4/6 highlights a strategy to target RB mutant cells while sparing RB wild-type cells.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC ABT-348 is a novel, potent and orally bioavailable… 
Review
2012
Review
2012
Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.
Abstract 2617 Introduction: ABT-348 is a potent, novel, adenosine triphospate competitive inhibitor of Aurora A, B and C kinases… 
2012
2012
Abstract 858: Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The Aurora kinases are a family of serine… 
2012
2012
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)